Recommendations Developed for Lymphangioleiomyomatosis

This article originally appeared here.
Share this content:
Recommendations Developed for Lymphangioleiomyomatosis
Recommendations Developed for Lymphangioleiomyomatosis

WEDNESDAY, Nov. 29, 2017 (HealthDay News) -- Evidence-based recommendations have been developed for the diagnosis and treatment of patients with lymphangioleiomyomatosis (LAM), and published in the Nov. 15 issue of the American Journal of Respiratory and Critical Care Medicine.

Nishant Gupta, M.D., from the University of Cincinnati, and colleagues conducted systematic reviews and developed recommendations for four specific questions related to LAM diagnosis and management of pneumothoraces in patients with LAM. For each intervention, the effects, balance of desirable and undesirable consequences, patient values and preferences, cost, and feasibility were considered.

The researchers made conditional recommendations against making a clinical diagnosis of LAM for women who have cystic changes on high-resolution computed tomography of the chest characteristic of LAM, but who have no additional confirmatory features of LAM, and recommended against considering transbronchial lung biopsy as a diagnostic tool. Conditional recommendations were made for offering pleurodesis after an initial pneumothorax, rather than delaying until the first recurrence, and against use of pleurodesis as a reason for excluding patients from lung transplant.

"The body of evidence the guidelines committee had to work with was small, and we identified several research directions that would greatly strengthen future recommendations," Gupta said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry; one author holds a patent for the use of vascular endothelial growth factor-D in the diagnosis of LAM.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »